Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.45 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1165785 | 0.98 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2MMP9MMP8 | |
| SCHEMBL27663465 | 0.94 | FFAR1 (0.50) | SMN1; SMN2MMP9MMP8MMP13FFAR1 | |
| SCHEMBL21624573 | 0.88 | LMNA (0.53) | NPC1RAB9ASMN1; SMN2MMP9MMP8 | |
| SCHEMBL4298983 | 0.87 | FFAR1 (0.49) | SMN1; SMN2LMNAALDH1A1FFAR1 | |
| SCHEMBL29033399 | 0.83 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2LMNATSHR | |
| SCHEMBL27396397 | 0.82 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2LMNATSHR | |
| SCHEMBL4759813 | 0.81 | FFAR1 (0.44) | SMN1; SMN2FFAR1 | |
| SCHEMBL28042429 | 0.81 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LMNATSHR | |
| SCHEMBL28042226 | 0.81 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LMNATSHR | |
| SCHEMBL28042428 | 0.81 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-20260014169-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | AZURITY PHARMACEUTICALS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250281509-A1 | SEQUENTIAL HORMONE THERAPY TO IMPROVE SURVIVAL AND ENHANCE RESPONSE TO IMMUNE THERAPY IN MEN WITH PROSTATE CANCER | THE JOHNS HOPKINS UNIVERSTY | 2025-09-11 | — | — | US | disclosed |
| WO-2025054607-A1 | COMPOSITIONS AND METHODS FOR TREATING SARCOPENIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20250032508-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SLAYBACK PHARMA LLC (US) | 2025-01-30 | — | — | US | disclosed |
| US-12138271-B2 | Pharmaceutical compositions of testosterone | SLAYBACK PHARMA LLC (US) | 2024-11-12 | — | — | US | disclosed |
| US-20230248742-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SLAYBACK PHARMA LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11642355-B2 | Pharmaceutical compositions of testosterone | SLAYBACK PHARMA LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220202830-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SLAYBACK PHARMA LLC (US) | 2022-06-30 | — | — | US | disclosed |
| US-11311554-B2 | Pharmaceutical compositions of testosterone | SLAYBACK PHARMA LLC (US) | 2022-04-26 | — | — | US | disclosed |
| US-20190307772-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SLAYBACK PHARMA LLC (US) | 2019-10-10 | — | — | US | disclosed |
| EP-2068840-A2 | HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM | LAB International SRL (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-2049087-A2 | HYDROPHILIC ABUSE DETERRENT DELIVERY SYSTEM | LAB International SRL (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008011595-A9 | HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM | LAB INTERNAT SRL (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008011595-A2 | HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM | LAB INTERNATIONAL SRL (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011596-A2 | HYDROPHILIC ABUSE DETERRENT DELIVERY SYSTEM | LAB INTERNATIONAL SRL (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1727520-A2 | METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS | MEDCRYSTALFORMS, LLC (US) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005055983-A2 | METHOD OF PREPARATION OF MIXED PHASE CO-CRYSTALS WITH ACTIVE AGENTS | MEDCRYSTALFORMS, LLC (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014169-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SHBG, CYP17A1, AR | NPC1 348/4885RAB9A 3325/4885SMN1; SMN2 855/4885 |
| US-20230248742-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SHBG, CYP17A1, NR5A1 | NPC1 1150/4885RAB9A 3930/4885SMN1; SMN2 833/4885 |
| US-11311554-B2 | Pharmaceutical compositions of testosterone | SHBG, CYP17A1, NR5A1 | NPC1 966/4885RAB9A 4150/4885SMN1; SMN2 1149/4885 |
| US-12138271-B2 | Pharmaceutical compositions of testosterone | SHBG, CYP17A1, NR5A1 | NPC1 1150/4885RAB9A 3930/4885SMN1; SMN2 833/4885 |
| US-11642355-B2 | Pharmaceutical compositions of testosterone | SHBG, CYP17A1, NR5A1 | NPC1 961/4885RAB9A 4138/4885SMN1; SMN2 1127/4885 |
| US-20190307772-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SHBG, CYP17A1, NR5A1 | NPC1 966/4885RAB9A 4150/4885SMN1; SMN2 1149/4885 |
| US-20220202830-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SHBG, CYP17A1, NR5A1 | NPC1 961/4885RAB9A 4138/4885SMN1; SMN2 1127/4885 |
| US-20250032508-A1 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE | SHBG, CYP17A1, NR5A1 | NPC1 1150/4885RAB9A 3930/4885SMN1; SMN2 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.